Global Neurodegenerative Diseases Market

Neurodegenerative Diseases Comprehensive Study by Application (Alzheimer's Disease, Huntington Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis), Drug Type (N-methyl-D-aspartate Receptor, Dopamine Inhibitors, Selective Serotonin Reuptake Inhibitor, Other Drug) Players and Region - Global Market Outlook to 2026

Neurodegenerative Diseases Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The brain is a complex organ with a vast number of the pathway that allows doing different activities. Brain is made up of billions of cells which are responsible for every second of everyday proper functioning. Some of the most important cells in the brain are called neurons. Neuron communicates with each other to perform every function of brain whether it involves movement, thinking, talking or remembering of things. When the cell of the brain are closely connected and miscommunicated in one area, it disrupts the other brain activities and leads to disease. Neurodegenerative disease is a term for a range of condition which primarily affects the neurons in the human brain. It occurs when the nerve cell in the brain or peripheral nervous system lose function over time and dies. These diseases are incurable and cause problems with movement or mental functioning (called dementias). The risk of this is being affected by the disease increases with age. Neurodegenerative diseases include Alzheimer's, multiple sclerosis, Huntington's disease, Parkinson's disease, multiple system atrophy, spinal muscular atrophy, and others. Change in lifestyles such as unhealthy eating habits, improper sleeping, and high-stress levels are likely to result in degenerative of nerve cells.This growth is primarily driven by Rising Prevalence of Neurological Disorder among All Genders, Races and Geographical Backgrounds, Increased Focus in Patient-Centric Healthcare Delivery and Growing Awareness about Neurodegenerative Diseases.

Globally, a noticeable market trend is evident Innovation in Neurodegenerative Disease Drug Discovery . Major Players, such as Novartis (Switzerland), Merck Serono (United States), Teva Pharmaceutical (Isreal), Pfizer (United States), Biogen Idec (United States), Bayer Schering Pharma AG (Germany), Boehringer Ingelheim (Germany), Amarin Corporation (Ireland), AstraZeneca (United Kingdom), Alector (United States), Yumanity Therapeutics (United States), Yangtze River Pharmaceutical Group (China) and Chongqing Zein Pharmaceutical (China) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
According to the study of Parkinson’s Association in 2018, around 1.2 million people in the U.S are estimated to be suffering from Parkinson’s disease by 2030. As per the Alzheimer’s Association, around 5.4 million Americans were suffering from Alzheimer’s in the year 2016. Moreover, this disease is more prevalent among people aged 65 years and above.

Market Drivers
  • Rising Prevalence of Neurological Disorder among All Genders, Races and Geographical Backgrounds
  • Increased Focus in Patient-Centric Healthcare Delivery
  • Growing Awareness about Neurodegenerative Diseases

Market Trend
  • Innovation in Neurodegenerative Disease Drug Discovery
  • Remote Monitoring and Growing Focus on Consumer-Centric Mobility Solutions

Restraints
  • Stringent Government Rules and Regulations
  • High Cost Associated With Neurodegenerative Disease
  • Patent Expiry of Neurodegenerative Disease Treatment Products

Opportunities
Rising Incidence Due To Change In Lifestyle Such As Improper Sleeping, High-Stress Levels, And Unhealthy Eating Habits
Challenges
Dearth of Skilled Professionals to Treat Neurodegenerative Diseases

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Neurodegenerative Diseases Study Sheds Light on
— The Neurodegenerative Diseases Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Neurodegenerative Diseases industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Neurodegenerative Diseases industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Alzheimer's Disease
  • Huntington Disease
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis
By Drug Type
  • N-methyl-D-aspartate Receptor
  • Dopamine Inhibitors
  • Selective Serotonin Reuptake Inhibitor
  • Other Drug

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Neurological Disorder among All Genders, Races and Geographical Backgrounds
      • 3.2.2. Increased Focus in Patient-Centric Healthcare Delivery
      • 3.2.3. Growing Awareness about Neurodegenerative Diseases
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Skilled Professionals to Treat Neurodegenerative Diseases
    • 3.4. Market Trends
      • 3.4.1. Innovation in Neurodegenerative Disease Drug Discovery
      • 3.4.2. Remote Monitoring and Growing Focus on Consumer-Centric Mobility Solutions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurodegenerative Diseases, by Application, Drug Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neurodegenerative Diseases (Value)
      • 5.2.1. Global Neurodegenerative Diseases by: Application (Value)
        • 5.2.1.1. Alzheimer's Disease
        • 5.2.1.2. Huntington Disease
        • 5.2.1.3. Parkinson's Disease
        • 5.2.1.4. Amyotrophic Lateral Sclerosis
      • 5.2.2. Global Neurodegenerative Diseases by: Drug Type (Value)
        • 5.2.2.1. N-methyl-D-aspartate Receptor
        • 5.2.2.2. Dopamine Inhibitors
        • 5.2.2.3. Selective Serotonin Reuptake Inhibitor
        • 5.2.2.4. Other Drug
      • 5.2.3. Global Neurodegenerative Diseases Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Neurodegenerative Diseases (Price)
  • 6. Neurodegenerative Diseases: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck Serono (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical (Isreal)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biogen Idec (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer Schering Pharma AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amarin Corporation (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Alector (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Yumanity Therapeutics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Yangtze River Pharmaceutical Group (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Chongqing Zein Pharmaceutical (China)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Neurodegenerative Diseases Sale, by Application, Drug Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neurodegenerative Diseases (Value)
      • 7.2.1. Global Neurodegenerative Diseases by: Application (Value)
        • 7.2.1.1. Alzheimer's Disease
        • 7.2.1.2. Huntington Disease
        • 7.2.1.3. Parkinson's Disease
        • 7.2.1.4. Amyotrophic Lateral Sclerosis
      • 7.2.2. Global Neurodegenerative Diseases by: Drug Type (Value)
        • 7.2.2.1. N-methyl-D-aspartate Receptor
        • 7.2.2.2. Dopamine Inhibitors
        • 7.2.2.3. Selective Serotonin Reuptake Inhibitor
        • 7.2.2.4. Other Drug
      • 7.2.3. Global Neurodegenerative Diseases Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Neurodegenerative Diseases (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurodegenerative Diseases: by Application(USD Million)
  • Table 2. Neurodegenerative Diseases Alzheimer's Disease , by Region USD Million (2015-2020)
  • Table 3. Neurodegenerative Diseases Huntington Disease , by Region USD Million (2015-2020)
  • Table 4. Neurodegenerative Diseases Parkinson's Disease , by Region USD Million (2015-2020)
  • Table 5. Neurodegenerative Diseases Amyotrophic Lateral Sclerosis , by Region USD Million (2015-2020)
  • Table 6. Neurodegenerative Diseases: by Drug Type(USD Million)
  • Table 7. Neurodegenerative Diseases N-methyl-D-aspartate Receptor , by Region USD Million (2015-2020)
  • Table 8. Neurodegenerative Diseases Dopamine Inhibitors , by Region USD Million (2015-2020)
  • Table 9. Neurodegenerative Diseases Selective Serotonin Reuptake Inhibitor , by Region USD Million (2015-2020)
  • Table 10. Neurodegenerative Diseases Other Drug , by Region USD Million (2015-2020)
  • Table 11. South America Neurodegenerative Diseases, by Country USD Million (2015-2020)
  • Table 12. South America Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 13. South America Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 14. Brazil Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 15. Brazil Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 16. Argentina Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 17. Argentina Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 18. Rest of South America Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 19. Rest of South America Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 20. Asia Pacific Neurodegenerative Diseases, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 22. Asia Pacific Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 23. China Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 24. China Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 25. Japan Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 26. Japan Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 27. India Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 28. India Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 29. South Korea Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 30. South Korea Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 31. Taiwan Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 32. Taiwan Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 33. Australia Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 34. Australia Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 37. Europe Neurodegenerative Diseases, by Country USD Million (2015-2020)
  • Table 38. Europe Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 39. Europe Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 40. Germany Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 41. Germany Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 42. France Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 43. France Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 44. Italy Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 45. Italy Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 46. United Kingdom Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 47. United Kingdom Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 48. Netherlands Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 49. Netherlands Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 50. Rest of Europe Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 51. Rest of Europe Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 52. MEA Neurodegenerative Diseases, by Country USD Million (2015-2020)
  • Table 53. MEA Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 54. MEA Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 55. Middle East Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 56. Middle East Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 57. Africa Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 58. Africa Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 59. North America Neurodegenerative Diseases, by Country USD Million (2015-2020)
  • Table 60. North America Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 61. North America Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 62. United States Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 63. United States Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 64. Canada Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 65. Canada Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 66. Mexico Neurodegenerative Diseases, by Application USD Million (2015-2020)
  • Table 67. Mexico Neurodegenerative Diseases, by Drug Type USD Million (2015-2020)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Neurodegenerative Diseases: by Application(USD Million)
  • Table 82. Neurodegenerative Diseases Alzheimer's Disease , by Region USD Million (2021-2026)
  • Table 83. Neurodegenerative Diseases Huntington Disease , by Region USD Million (2021-2026)
  • Table 84. Neurodegenerative Diseases Parkinson's Disease , by Region USD Million (2021-2026)
  • Table 85. Neurodegenerative Diseases Amyotrophic Lateral Sclerosis , by Region USD Million (2021-2026)
  • Table 86. Neurodegenerative Diseases: by Drug Type(USD Million)
  • Table 87. Neurodegenerative Diseases N-methyl-D-aspartate Receptor , by Region USD Million (2021-2026)
  • Table 88. Neurodegenerative Diseases Dopamine Inhibitors , by Region USD Million (2021-2026)
  • Table 89. Neurodegenerative Diseases Selective Serotonin Reuptake Inhibitor , by Region USD Million (2021-2026)
  • Table 90. Neurodegenerative Diseases Other Drug , by Region USD Million (2021-2026)
  • Table 91. South America Neurodegenerative Diseases, by Country USD Million (2021-2026)
  • Table 92. South America Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 93. South America Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 94. Brazil Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 95. Brazil Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 96. Argentina Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 97. Argentina Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 98. Rest of South America Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 99. Rest of South America Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 100. Asia Pacific Neurodegenerative Diseases, by Country USD Million (2021-2026)
  • Table 101. Asia Pacific Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 102. Asia Pacific Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 103. China Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 104. China Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 105. Japan Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 106. Japan Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 107. India Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 108. India Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 109. South Korea Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 110. South Korea Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 111. Taiwan Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 112. Taiwan Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 113. Australia Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 114. Australia Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 115. Rest of Asia-Pacific Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 116. Rest of Asia-Pacific Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 117. Europe Neurodegenerative Diseases, by Country USD Million (2021-2026)
  • Table 118. Europe Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 119. Europe Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 120. Germany Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 121. Germany Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 122. France Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 123. France Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 124. Italy Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 125. Italy Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 126. United Kingdom Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 127. United Kingdom Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 128. Netherlands Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 129. Netherlands Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 130. Rest of Europe Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 131. Rest of Europe Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 132. MEA Neurodegenerative Diseases, by Country USD Million (2021-2026)
  • Table 133. MEA Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 134. MEA Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 135. Middle East Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 136. Middle East Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 137. Africa Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 138. Africa Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 139. North America Neurodegenerative Diseases, by Country USD Million (2021-2026)
  • Table 140. North America Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 141. North America Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 142. United States Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 143. United States Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 144. Canada Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 145. Canada Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 146. Mexico Neurodegenerative Diseases, by Application USD Million (2021-2026)
  • Table 147. Mexico Neurodegenerative Diseases, by Drug Type USD Million (2021-2026)
  • Table 148. Research Programs/Design for This Report
  • Table 149. Key Data Information from Secondary Sources
  • Table 150. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurodegenerative Diseases: by Application USD Million (2015-2020)
  • Figure 5. Global Neurodegenerative Diseases: by Drug Type USD Million (2015-2020)
  • Figure 6. South America Neurodegenerative Diseases Share (%), by Country
  • Figure 7. Asia Pacific Neurodegenerative Diseases Share (%), by Country
  • Figure 8. Europe Neurodegenerative Diseases Share (%), by Country
  • Figure 9. MEA Neurodegenerative Diseases Share (%), by Country
  • Figure 10. North America Neurodegenerative Diseases Share (%), by Country
  • Figure 11. Global Neurodegenerative Diseases share by Players 2020 (%)
  • Figure 12. Global Neurodegenerative Diseases share by Players (Top 3) 2020(%)
  • Figure 13. Global Neurodegenerative Diseases share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 17. Merck Serono (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck Serono (United States) Revenue: by Geography 2020
  • Figure 19. Teva Pharmaceutical (Isreal) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical (Isreal) Revenue: by Geography 2020
  • Figure 21. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer (United States) Revenue: by Geography 2020
  • Figure 23. Biogen Idec (United States) Revenue, Net Income and Gross profit
  • Figure 24. Biogen Idec (United States) Revenue: by Geography 2020
  • Figure 25. Bayer Schering Pharma AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer Schering Pharma AG (Germany) Revenue: by Geography 2020
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 29. Amarin Corporation (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Amarin Corporation (Ireland) Revenue: by Geography 2020
  • Figure 31. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Alector (United States) Revenue, Net Income and Gross profit
  • Figure 34. Alector (United States) Revenue: by Geography 2020
  • Figure 35. Yumanity Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Yumanity Therapeutics (United States) Revenue: by Geography 2020
  • Figure 37. Yangtze River Pharmaceutical Group (China) Revenue, Net Income and Gross profit
  • Figure 38. Yangtze River Pharmaceutical Group (China) Revenue: by Geography 2020
  • Figure 39. Chongqing Zein Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 40. Chongqing Zein Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 41. Global Neurodegenerative Diseases: by Application USD Million (2021-2026)
  • Figure 42. Global Neurodegenerative Diseases: by Drug Type USD Million (2021-2026)
  • Figure 43. South America Neurodegenerative Diseases Share (%), by Country
  • Figure 44. Asia Pacific Neurodegenerative Diseases Share (%), by Country
  • Figure 45. Europe Neurodegenerative Diseases Share (%), by Country
  • Figure 46. MEA Neurodegenerative Diseases Share (%), by Country
  • Figure 47. North America Neurodegenerative Diseases Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • Merck Serono (United States)
  • Teva Pharmaceutical (Isreal)
  • Pfizer (United States)
  • Biogen Idec (United States)
  • Bayer Schering Pharma AG (Germany)
  • Boehringer Ingelheim (Germany)
  • Amarin Corporation (Ireland)
  • AstraZeneca (United Kingdom)
  • Alector (United States)
  • Yumanity Therapeutics (United States)
  • Yangtze River Pharmaceutical Group (China)
  • Chongqing Zein Pharmaceutical (China)
Additional players considered in the study are as follows:
Eisai (Japan) , H.Lundbeck A/S (Denmark) , Jiangsu Hansoh Pharmaceutical (China)
Select User Access Type

Key Highlights of Report


Jan 2022 202 Pages 53 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neurodegenerative Diseases Market Quantitative research analysis
Global Neurodegenerative Diseases Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Neurodegenerative Diseases Market are Novartis (Switzerland), Merck Serono (United States), Teva Pharmaceutical (Isreal), Pfizer (United States), Biogen Idec (United States), Bayer Schering Pharma AG (Germany), Boehringer Ingelheim (Germany), Amarin Corporation (Ireland), AstraZeneca (United Kingdom), Alector (United States), Yumanity Therapeutics (United States), Yangtze River Pharmaceutical Group (China) and Chongqing Zein Pharmaceutical (China) etc.
The brain is a complex organ with a vast number of the pathway that allows doing different activities. Brain is made up of billions of cells which are responsible for every second of everyday proper functioning. Some of the most important cells in the brain are called neurons. Neuron communicates with each other to perform every function of brain whether it involves movement, thinking, talking or remembering of things. When the cell of the brain are closely connected and miscommunicated in one area, it disrupts the other brain activities and leads to disease. Neurodegenerative disease is a term for a range of condition which primarily affects the neurons in the human brain. It occurs when the nerve cell in the brain or peripheral nervous system lose function over time and dies. These diseases are incurable and cause problems with movement or mental functioning (called dementias). The risk of this is being affected by the disease increases with age. Neurodegenerative diseases include Alzheimer's, multiple sclerosis, Huntington's disease, Parkinson's disease, multiple system atrophy, spinal muscular atrophy, and others. Change in lifestyles such as unhealthy eating habits, improper sleeping, and high-stress levels are likely to result in degenerative of nerve cells.

Know More About Global Neurodegenerative Diseases Market Report?

Have a Query? Click Here

Other Related Reports

New Generation Implants Comprehensive Study by Type (Endosteal,, Subperiosteal,, Zygomatic.), Application (Orthopedic Implants, Cardiovascular Implants, Ocular Implants, Dental Implants), Raw Materia...
$ 3500
Bartter Syndrome Treatment Comprehensive Study by Type (Medication, Therapy), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Genes Types (LC12A1 Gene, KCNJ1 Gene, CLCNKB Gen...
$ 3750
Nasopharyngeal Cancer Comprehensive Study by Type (Keratinizing Squamous Cell Carcinoma, Nonkeratinizing Squamous Cell Carcinoma, Undifferentiated or Poorly Differentiated), Application (Hospitals, C...
$ 3650
Pituitary cancer Comprehensive Study by Type (Surgery, Endoscopic Transnasal Transsphenoidal Surgery, Craniotomy, Radiation Therapy, Stereotactic Radiosurgery, External beam radiation, Intensity Modu...
$ 3750
Chronic Traumatic Encephalopathy (CTE) Comprehensive Study by Type (Medical Treatment, Physical Therapy), Application (Athletes, Military Veterans, Other), End Users (Hospital & Clinic, Diagnostic Ce...
$ 3650
Progressive Multifocal Leukoencephalopathy Treatment Comprehensive Study by Type (Anti-Retroviral Therapy, Antiviral/Anti JCV, Other Symptomatic), Application (Hospital Pharmacies, Drug Stores, Retai...
$ 3750